Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral BEZ235 monotherapy in HR-positive, HER2-negative metastatic breast cancer
2010-024394-39Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in breast cancer and endometrial cancer (EC), sponsored by Novartis. Primary endpoint: 16-week Progression Free Survival Rate. Started Feb 2011; status: terminated.
02
Drugs
dactolisib
03
Conditions
breast cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2010-024394-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024394-39.